Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | AOC2 | O75106 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.51 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.47 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.47 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.47 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27988046 | 0.94 | MAOB (0.55) | FFAR1TAAR1MAOBAOC2MAOA | |
| SCHEMBL7011662 | 0.92 | FFAR1 (0.67) | FFAR1SLC5A1SLC5A2PLAAT3PLAAT5 | |
| SCHEMBL4846241 | 0.91 | LMNA (0.54) | FFAR1TAAR1MAOBAOC2MAOA | |
| SCHEMBL658360 | 0.89 | LMNA (0.54) | FFAR1TAAR1MAOBAOC2MAOA | |
| SCHEMBL2170992 | 0.89 | FFAR1 (0.53) | FFAR1MAOBAOC2MAOAAOC3 | |
| SCHEMBL2170069 | 0.89 | FFAR1 (0.46) | FFAR1TAAR1MAOBAOC2MAOA | |
| SCHEMBL1478337 | 0.88 | NAAA (0.51) | FFAR1TAAR1SLC5A1SLC5A2LMNA | |
| SCHEMBL15672830 | 0.88 | ALDH1A1 (0.48) | FFAR1TAAR1MAOBAOC2MAOA | |
| SCHEMBL31577212 | 0.86 | NAAA (0.50) | FFAR1TAAR1LMNAMPO | |
| SCHEMBL29655601 | 0.86 | NAAA (0.50) | FFAR1TAAR1LMNAMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114539158-B | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2023-12-08 | — | — | CN | claimed |
| EP-4188551-A1 | ARYL SUBSTITUTED PYRROLO-PYRIDINONES AND THERAPEUTIC USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-06-07 | — | — | EP | claimed |
| CN-114539158-A | FXIa inhibitor compound and preparation method and application thereof | 沈阳药科大学 | 2022-05-27 | — | — | CN | claimed |
| EP-3921317-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | Bayer Aktiengesellschaft (DE) | 2021-12-15 | — | — | EP | claimed |
| WO-2020161257-A1 | 3-AMINO-2-[2-(ACYLAMINO)PYRIDIN-4-YL]-1,5,6,7-TETRAHYDRO-4H-PYRROLO[3,2-C]PYRIDIN-4-ONE AS CSNK1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2020-08-13 | — | — | WO | claimed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | claimed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | claimed |
| US-9198426-B2 | Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-12-01 | — | — | US | claimed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | claimed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | claimed |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2006-11-09 | — | — | US | claimed |
| WO-2006086445-A2 | COMBINATION THERAPY | XENON PHARMACEUTICALS INC. (CA) | 2006-08-17 | — | — | WO | claimed |
| EP-1651620-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| EP-1651605-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-05-03 | — | — | EP | claimed |
| EP-1648874-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2006-04-26 | — | — | EP | claimed |
| EP-1067113-B1 | Process for the preparation of phenethylamines and intermediates therefor | LANXESS DEUTSCHLAND GMBH (DE) | 2005-07-20 | — | — | EP | claimed |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2005-03-24 | — | — | US | claimed |
| WO-2005011655-A2 | PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2005011654-A2 | PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
| WO-2005011657-A2 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2005-02-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | JAK1, CNKSR1, TSHR | FFAR1 37/4885TAAR1 34/4885MAOB 1360/4885 |
| US-20050065143-A1 | Pyridazine derivatives and their use as therapeutic agents | PRDX5, SNRPD3, SNRPD2 | FFAR1 741/4885TAAR1 2591/4885MAOB 1042/4885 |
| US-20060252767-A1 | Piperazine derivatives and their use as therapeutic agents | ARG2, S1PR5, S1PR1 | FFAR1 250/4885TAAR1 3140/4885MAOB 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.